such as EGFR or the PI3K–Akt–mTOR pathway, will lead to improved results of anticancer therapy. Moreover, at present, little is known about the outcome of gastric cancer patients after ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

The company also shared initial data from its DisTinGuish study in gastric cancer, which did not meet ... those who have experienced anti-EGFR therapy, and those with RAS wildtype tumors.

Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.

Yeah, so the EGFR mutation lung cancer field has really expanded. We usually think about EGFR as the classical mutation, deletion 19 and 858R mutation. But in the last, I will say, five to 10 ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Last couple of years, we have seen a lot of new excitement in treating EGFR mutation lung cancer. I will have to comment on the frontline setting. We had two international global randomized phase ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

for the treatment of diffuse gastric cancer (DGC) and other advanced solid tumors. This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...